Magnetic Resonance Imaging Assessment of Multiorgan Health in Obesity

NCT07702825 | Recruiting

• 1 other identifier: 349237
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to quantify the body composition and organ fat distribution changes with obesity interventions in adolescents with severe obesity. The main question the investigators aim to answer is if there is improvement in organ health with weight loss intervention. The investigators will be comparing the degree of these changes between children being treated with GLP1 receptor agonists in addition to lifestyle changes and those managed with lifestyle changes alone. Participants will undergo MRI body composition at baseline and after 9 months.

Conditions

Childhood Obesity

Keywords

Obesity; GLP1 receptor agonist; MRI Body composition

Outcome Measures

Primary Outcomes (1)

• Change in Liver fat measured using quantitative MRI

  Change in liver fat content from baseline to follow-up, quantified using MRI-derived proton density fat fraction (PDFF).

  From enrollment to 9 months

Secondary Outcomes (4)

• Changes to body composition assessed by MRI

  Baseline to 9 months

• Change in pancreatic fat assessed by MRI.

  Baseline to 9 months

• Changes in biochemical parameters-fasting glucose

  9 months

• Changes in biochemical parameters-HbA1C

  9 months

Other Outcomes (1)

• Change in sleep study parameter

  9 months

Study Arms (2)

Patients on GLP1 receptor agonist

Patients being treated with GLP1 receptor agonist in addition to lifestyle interventions

Patients not on GLP1 receptor agonist

Patients not being treated with GLP1 receptor agonist and only on lifestyle intervention

Eligibility Criteria

• Age: 12 Years - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Eligible adolescents under the care of the tertiary weight management service (Complications from Excess Weight service) at Alder Hey Children's hospital will be offered to enrol in the study once a decision has been taken whether or not they are being started on GLP1 receptor agonist treatment.

You may qualify if:

• Age 12 to \<18 years at the time of enrolment
• BMI \>99.6th centile or \>2.67 SDS
• Informed consent from parent(s) (or person with parental responsibility) and assent from the child or young person for participants aged less than 16 years (or)
• Informed consent from the participant if aged ≥ 16 years.

You may not qualify if:

• Body weight above upper limit of the scanner (\>250 kilograms)
• Needs general anaesthesia for the MRI scanning
• Any contraindications for MRI- Metal implants/claustrophobia
• Previous use of GLP-1 receptor agonist
• Refusal to consent or refusal to assent from a competent older adolescent.

Sponsors & Collaborators

• Alder Hey Children's NHS Foundation Trust: lead

Study Sites (1)

Alder Hey Children's hospital

Liverpool, Merseyside, L122AP, United Kingdom

RECRUITING

MeSH Terms

Conditions

Pediatric Obesity; Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Anand Ramakrishnan, MD (Ped), MSc (Diab), PhD endo

CONTACT

+44 01512525956; senthil.senniappan@alderhey.nhs.uk

Anand Ramakrishnan, MBBS, MD, MRCPCH, DipUKMP

CONTACT

07404613764; anand.ramakrishnan@alderhey.nsh.uk

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 9 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: July 14, 2026
• Study Start: March 6, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): January 1, 2028
• Last Updated: July 14, 2026

Record last verified: 2026-07

Locations

GB (1)